Clinical trialNCT03755804Active, not recruitingPhase 2Interventional

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

SponsorSt. Jude Children's Research HospitalEnrollment232Hodgkin Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment. Low-risk and intermediate- risk patients will be treated with bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine, and prednisone (BEABOVP) chemotherapy. High-risk patients will receive Adcetris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxorubicin) (AEPA) and cyclophosphamide, Adcetris® (brentuximab vedotin), prednisone and Dacarbazine® (DTIC) (CAPDac) chemotherapy. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an adequate response (AR) after 2 cycles of therapy for all risk groups.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Matthew Ehrhardt, MD, MS
St. Jude Children's Research Hospital
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Lucile Packard Children'S Hospital Stanford University
Palo Alto, California, United States
St. Jude Midwest Affiliate - Peoria
Peoria, Illinois, United States
St. Jude Affiliate Baton Rouge Clinic (our Lady of the Lakes Regional Medical Center)
Baton Rouge, Louisiana, United States
Maine Children'S Cancer Program
Scarborough, Maine, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
St. Jude Affiliate Clinic at Novant Health Hemby Children'S Hospital
Charlotte, North Carolina, United States
St. Jude Children'S Research Hospital
Memphis, Tennessee, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bleomycin →Brentuximab vedotin →Cyclophosphamide →DacarbazineDoxorubicin →Etoposide →Filgrastim →Prednisone →VinblastineVincristine →Bendamustine →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 12 Dec 2018
Primary completion: 1 Jan 2027
Completion: 1 Jul 2028
Last update posted: 17 Jun 2026
Registered enrollment: 232
Registry id: NCT03755804

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.